source
- Otsuka presents long-term Phase 3 data for Voyxact, aiming to secure full FDA approval for kidney diseaseOtsuka announced new long-term results from the Phase 3 trial of its kidney disease drug Voyxact. The data show that the therapy stabilized kidney function over an extended period, building on ear…
- Celea Therapeutics secures $180M financing to advance IPF pipelineCelea Therapeutics, an idiopathic pulmonary fibrosis (IPF) biotech, announced it has raised $180 million from a group of new investors. The funding is intended to help the company follow the devel…